Table 6.
Selected series reported > 5% Grade 2 toxicities.
| Author | Year | Schedule | BED α/β = 1.5 | Median follow-up | Late GU | Late GI |
|---|---|---|---|---|---|---|
| Aluwini | 2013 | 38 Gy/4 fr | 278.7 Gy | 28.35 months |
G2: 15% G3: 5% |
G2: 3% |
| Chen | 2013 | 35–36.5 Gy/5 fr | 198–211.5 Gy | 27.6 months | G2: 31% (2-year) | G2: 1% (2-year) |
| Meier | 2018 | 40 Gy/5 fr | 253.3 Gy | 61 months |
G2: 12% G3: 1.3% |
G2: 2% |
| Katz | 2017 | 35–36.5 Gy/5 fr | 198–211.5 Gy | 108 months |
G2: 9% G3: 3% |
G2: 4% |
| Zimmermann | 2016 | 45 Gy/9 fr | 315 Gy | 83 months |
G2: 27.5% G3: 2.5% G4: 1.3% |
G2: 17.5% G3: 12.5% |
| Kim | 2014 | 45–50 Gy/5 fr | 315–383.3 Gy | 24.5 months | NA |
G4: 2.2% G3: 3.3% G2: 23.1% |
| Bernetich | 2014 | 35–37.5 Gy/5 fr | 198–225 Gy | 38 months |
G2: 14% G3: 2% |
G2: 3% |
| Zhang | 2017 | 38 Gy/4 fr | 278.7 Gy | 35.5 months |
G2: 19.2% G3: 2.6% |
NA |
| Helou | 2017 | 35–40 Gy/5 fr | 198–253.3 Gy | 38 months |
G3: 1.9% G2: 32.6% |
G2: 12.0% G3: 0.8% G4: 1.1% |
BED biologically effective dose, GU genitourinary, GI gastrointestinal.